Tolazine® Injection (tolazoline HCl, USP)

Alpha-2 antagonist. For use as indicated in equine AnaSed® (xylazine sterile solution) Injection reversal.

- Alpha-adrenergic receptor antagonist
- Reverses the effects of sedation and analgesia
- Rapidly restores reflexes and ambulation
- Reverses xylazine-induced GI hypomotility
- Manufactured in the U.S.A.

Tolazine® is uniquely effective for the rapid reversal of AnaSed® in horses. It provides for a well-controlled and predictable recovery resulting in accelerated reflex and ambulation restoration.

Tolazine® also provides the added benefit of xylazine-induced GI hypomotility correction. For safe and cost-effective AnaSed® reversal, veterinarians consistently trust Akorn Animal Health brand Tolazine® to get their patients back on their feet.

NADA #140-994, Approved by FDA
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Tolazine® Injection
Tolazine HCl, USP
100 mg Tolazine per mL
Sterile Solution
Xylazine Reversing Agent and Antagonist
For Intravenous Use in Horses Only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Tolazine contains tolazoline hydrochloride with the chemical name 1H-imidazole, 4,5-dihydro-2-(phenylmethyl) -monohydrochloride. Tolazine hydrochloride has a molecular weight of 196.68 and the molecular formula is C10H12N2•HCl. The structural formula is

![Structural formula of Tolazine](image)

Each mL contains: tolazoline hydrochloride equivalent to 100 mg base activity, chlorobutanol 5.0 mg, tartaric acid 7.8 mg, sodium citrate dihydrate 7.8 mg and water for injection. The pH is adjusted with hydrochloric acid and sodium citrate.

CLINICAL PHARMACOLOGY: Tolazine belongs to the synthetic group of alpha-adrenergic blocking agents known as the imidazoline derivatives. It is a mixed alpha-1 and alpha-2 adrenergic receptor antagonist that competitively inhibits alpha-adrenergic receptors. Tolazine is also a direct peripheral vasodilator that decreases the peripheral resistance and increases venous capacitance.

Xylazine is an alpha-2 adrenergic agonist with sedative and analgesic properties related to central nervous system depression. Administration of Tolazine reverses xylazine’s central nervous system depressant effects resulting in rapid recovery from sedation. The competitive blocking of the alpha-2 adrenergic receptor by Tolazine displaces xylazine from these sites and thereby rapidly cancels the effect of the xylazine.

Onset of arousal is usually apparent within 5 minutes of Tolazine administration, depending on the depth and duration of xylazine induced sedation.

INDICATIONS: Tolazine should be used in horses when it is desirable to reverse the effects of sedation and analgesia caused by xylazine.

DOSE AND ADMINISTRATION: The Tolazine dose is 4.0 mg/kg body weight or 1.8 mg/lb (4 mL/100 kg or 4 mL/220 lb) to reverse the sedative effects of xylazine. The carefully calculated dose of Tolazine should be administered carefully and at a slow rate to allow venous dilution to occur prior to the drug reaching the brain and heart. An administration rate of 1 mL/second was shown to be safe at the recommended dose.

Side effects of xylazine used as a preanesthetic to a general anesthetic.

SAFETY: The safety of Tolazine alone without prior xylazine administration was evaluated in healthy horses. Tolazine was administered at 1, 5, and 5 times the recommended dose of 4 mg/kg, every 6 hours for 3 doses. When administered alone, Tolazine caused gastrointestinal hypermotility as horses defecated or attempted to defecate with flatulence within minutes after injection. Some horses exhibited abdominal discomfort (mild colic) and displayed transient diarrhea. Gastrointestinal disturbances were seen in all dose groups.

The safety of Tolazine was evaluated following administration of xylazine in healthy horses. The frequency of gastrointestinal disturbances was decreased in the presence of xylazine. Most horses experienced xylazine-induced hypomotility. A return to normal intestinal motility occurred within 5 minutes after Tolazine administration. A single incidence of mild colic was observed at three times the recommended Tolazine dose, and one instance of transient diarrhea was exhibited at three times the recommended Tolazine dose.

The heart rate may briefly increase immediately after Tolazine injection at the recommended dose with return to pretreatment rates within 5-10 minutes. The degree and duration of tachycardia increased with higher doses, although the increased rate usually lasted less than 60 minutes.

When Tolazine was administered at higher than the recommended dose in healthy horses, intraventricular conduction was slowed, as demonstrated by a prolongation of the QRS complex of the ECG. This effect was not observed at the 1X dose, only a mild prolongation occurred in a single horse at the 2X dose, and it was seen in most horses that received the 3X and 5X doses. Abnormalities of intraventricular conduction can predispose to ventricular arrhythmias and possibly death.

Overdoses of Tolazine at 5 times the recommended dose have been associated with fatalities in horses.

Tolazine at doses less than or equal to 5 times the recommended dose did not affect any hematology, serum biochemical, or urinalysis measurements.

WARNING: Keep out of reach of children. Not for human use. This drug is for use in horses only and not for use in food-producing animals.

Avoid contact with eyes, skin and mucous membranes. In case of eye contact flush with plenty of water. Exposed skin should be washed with soap and water. In case of accidental oral exposure or injection, seek emergency medical attention.

Users with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid accidental exposure to this product.

TO use this product should not be used to treat hypotension in humans resulting from exposure to this product since tolazoline may cause “epinephrine reversal” (further reduction in blood pressure, followed by an exaggerated rebound).

STORAGE: Protect from light. Store at controlled room temperature 15° to 30°C (59° to 86°F).

HOW SUPPLIED: NDC 59999-113-90 100 mL multiple-dose vial.

REFERENCES:

Manufactured by:
Akorn, Inc.
Lake Forest, IL 60045

TH00N Rev. 07/14

NOT FOR PRESCRIBING PURPOSES. PLEASE REFER TO PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION.